Cancer Research Technology
Log in Register
Menu

CAN I DEPOSIT OR ACCESS RESEARCH TOOLS THAT CONTAIN CRISPR-Cas9 TECHNOLOGY?

Deposit

If you have developed modified cell lines using CRISPR-Cas9 please get in touch.

Access

Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed below.  This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

ERS Genomics Ltd holds an exclusive worldwide license from Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 for all applications other than use as a human therapeutic. The patent rights belonging to ERS Genomics Ltd are listed below. These patent applications have broad and dominant claims covering CRISPR-Cas9 compositions and methods of genome editing in any organism. 

Click here to view ERS Genomics Ltd Granted Patents


Was this information useful? 23 5

see all FAQ's from this category >